Winship Deputy Director Suresh Ramalingam, MD and colleagues report encouraging results of FLAURA study, published in New England Journal of Medicine, involving NSCLC patients with an EGFR mutation treated with osimertinib.

In lung cancer patients who were taking immunotherapy drugs targeting the PD-1 pathway, testing for CD8 T cell activation in their blood partially predicted whether their tumors would shrink.

Suresh S. Ramalingam, MD, deputy director of Winship Cancer Institute of Emory University and assistant dean for cancer research in the Emory School of Medicine, was selected to hold the Roberto C. Goizueta Distinguished Chair for Cancer Research.

Emory's Winship Cancer Institute is using new drugs that work with a patient's own immune system to fight cancer.

Suresh S. Ramalingam, MD, an internationally recognized lung cancer physician-investigator, has been named deputy director of Winship Cancer Institute of Emory University. He will also serve as assistant dean for cancer research in the Emory School of Medicine.

Winship Cancer Institute clinicians and scientists work with their research partners across campus and the country to design, develop, and test new, personalized treatment regimens. Increasingly those regimens are specific to each patient.

Phase II clinical trial data presented at the 2013 ASCO meeting suggests the hsp90 inhibitor ganetespib in combination with docetaxel can be an effective second-line therapy for advanced lung cancer.

The phase 1 unit at the Winship Cancer Institute evaluates drugs given to cancer patients for the first time, advancing cures and bringing hope.

A breath test to detect established lung cancer showed promising results in a study by researchers at Winship Cancer Institute of Emory University and Georgia Institute of Technology.